- The FDA has granted emergency use authorization (EUA) to Qiagen N.V.’s (NYSE:QGEN) QIAreach SARS CoV-2 Antigen Test.
- The rapid, portable test can detect COVID-19 antigen in people with active infections in 2 to 15 minutes.
- The test can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation.
- The QIAreach test is the second Qiagen COVID-19 test to use the digital eHub and eStick system developed in partnership with Australian digital diagnostics company, Ellume.
- Lab professionals will now be able to run tests to detect both previous and active infections on one device simultaneously, with each testing slot operating independently of the others.
- Each Digital eHub device, with a capacity for up to 8 eSticks, can simultaneously run QIAreach COVID-19 antigen and antibody tests.
- Related: Qiagen Stock Gains As Non-COVID Sales Boosts Q2 Topline, Bottom-line.
- Price Action: QGEN shares closed down 0.72% at $52.36 on Friday.
- Related content: Benzinga’s Full FDA Calendar.
- Photo by Mufid Majnun on Unsplash
AECOM Wins an Engineering Contract from FEMA Worth Up to $300M For a 1-Year Base Period
AECOM (NYSE:ACM), the world's trusted infrastructure consulting firm, today announced the U.S. Department of Homeland Security's Federal Emergency Management Agency (FEMA) has awarded the AECOM-led Compass
